

**Midhun, Karen**

**From:** Baylor, Norman  
**Sent:** Tuesday, October 05, 2004 9:52 AM  
**To:** Midhun, Karen  
**Subject:** FW: Evans/Chiron update

**Importance:** High

FYI: This is what Roland informed me just a couple of weeks ago.

-----Original Message-----

**From:** Levandowski, Roland A.  
**Sent:** Monday, September 20, 2004 2:43 PM  
**To:** Egan, William; Baylor, Norman  
**Cc:** Weir, Jerry P.  
**Subject:** RE: Evans/Chiron update

As a further follow up: I spoke with Bruce Gellin who also called to ask if there was something happening. According to discussion with Bruce, the genesis of the rumor with Steve Cocchi appears to be related to an e-mail from Dixie Snider instructing CDC (?Steve Cocchi's group) to plan on purchasing another 2 million doses of vaccine. The e-mail was prefaced something to the effect of "after discussion with FDA" and somehow those words have been interpreted to be an ominous code. I don't know who Dixie would have been in touch with, but usually it would be one of you or Karen or Jesse, no?

-----Original Message-----

**From:** Levandowski, Roland A.  
**Sent:** Monday, September 20, 2004 1:34 PM  
**To:** Egan, William; Baylor, Norman  
**Cc:** Weir, Jerry P.  
**Subject:** Evans/Chiron update

Dear Bill and Norman:

It was no sooner than you had walked out the door when John O'Brien and Simon Bryson from Evans called (about 1:10 PM our time) to provide some information on status of vaccine. Their news was only good, so I have to believe that what you expressed about CDC having concern about vaccine supply must be a misunderstanding or some contract issue specific to CDC. John O'Brien indicates that the investigation at Evans is winding down and there are no sterility failures to report for any of the retested materials beyond what was already known. The two monovalent concentrate lots are still the likely root cause of the sterility failure, and the focus continues to be on the formulation department. John O'Brien indicates that Evans plans to restart shipping soon and plans to begin releasing vaccine next week. He also indicates that there will be another press release to make an announcement to that effect, probably Tuesday, if everything stays on track like it seems to be. They questioned whether we would have any special issues for them to go forward, and I said that I didn't think so, provided they are following SOPs, the product meets specifications and they believe that they have isolated and resolved the issue. I suggested that maybe John O'Brien should be in touch on this with Bill rather than me, because there may be others in the organization who need to know developments, and I don't know who all of those people are, necessarily.

Roland